The purpose of this study is to evaluate and compare the safety and pharmacokinetics of NVP-1402 and NVP-1402R in healthy male subjects.
This study is designed as randomized, open-label, active-controlled and crossover assignment for evaluate and compare the safety and pharmacokinetics of NVP-1402 and NVP-1402R in healthy male subjects. The safety assessed through adverse events up to 17 days after administration. Additional variables (ECGs, laboratory test, vital signs, so on) will also be recorded and assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
38
Navipharm
Suwon, Gyeonggi-do, South Korea
Pharmacokinetics of plasma: Cmax
Maximum measured concentration of the analyte in plasma
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: AUClast
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: AUCinf
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: Tmax
Time from dosing to the maximum measured concentration of the analyte in plasma
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: t1/2
Terminal half-life of the analyte in plasma
Time frame: up to 24 hours after administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.